Agios Pharmaceuticals, Inc. (AGIO) EPS Estimated At $-1.63

October 14, 2018 - By olga

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) LogoInvestors sentiment decreased to 1.48 in 2018 Q2. Its down 0.24, from 1.72 in 2018Q1. It is negative, as 16 investors sold Agios Pharmaceuticals, Inc. shares while 50 reduced holdings. 35 funds opened positions while 63 raised stakes. 52.36 million shares or 1.07% less from 52.93 million shares in 2018Q1 were reported.
Susquehanna Intll Group Incorporated Llp stated it has 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Btg Pactual Global Asset owns 0.21% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 8,586 shares. Massachusetts-based Loomis Sayles And Ltd Partnership has invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). First Trust Advsr Limited Partnership holds 0.13% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 731,794 shares. Morgan Stanley reported 89,200 shares. Moreover, Peak6 Investments Ltd Partnership has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Cap Ca, a California-based fund reported 15,300 shares. Hanseatic Inc owns 8,432 shares or 0.61% of their US portfolio. Profund Advsrs has 0.05% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 15,388 shares. Rhumbline Advisers reported 53,362 shares stake. Numerixs Technologies reported 1,100 shares. Bb Biotech Ag accumulated 2.20M shares or 5.35% of the stock. The New York-based X Limited Liability Corp has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Employees Retirement Association Of Colorado, a Colorado-based fund reported 7,075 shares. Moreover, Partner Fund Management L P has 0.81% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 614,506 shares.

Since April 12, 2018, it had 0 insider buys, and 21 sales for $17.57 million activity. 2,000 shares valued at $170,190 were sold by Bowden Christopher on Thursday, April 12. 2,050 shares were sold by Hoerter Steven L., worth $200,039. On Thursday, June 14 the insider Foster-Cheek Kaye I sold $841,926. Another trade for 3,000 shares valued at $245,430 was sold by Biller Scott. MARAGANORE JOHN had sold 27,717 shares worth $2.00M. 312 shares were sold by Alenson Carman, worth $25,896.

Analysts expect Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report $-1.63 EPS on November, 7.They anticipate $0.04 EPS change or 2.52 % from last quarter’s $-1.59 EPS. After having $-1.19 EPS previously, Agios Pharmaceuticals, Inc.’s analysts see 36.97 % EPS growth. The stock increased 3.98% or $2.52 during the last trading session, reaching $65.88. About 532,248 shares traded or 47.52% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 12.19% since October 14, 2017 and is uptrending. It has underperformed by 3.43% the S&P500.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 5 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Agios Pharmaceuticals had 5 analyst reports since May 23, 2018 according to SRatingsIntel. On Wednesday, May 30 the stock rating was initiated by Piper Jaffray with “Buy”. The firm has “Hold” rating given on Monday, June 18 by Oppenheimer.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $3.82 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More news for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on September 25, 2018. Globenewswire.com‘s article titled: “New Research Coverage Highlights Camden Property Trust, Agios Pharmaceuticals, Crane, BorgWarner, Cognizant …” and published on October 04, 2018 is yet another important article.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>